{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:15:54Z","timestamp":1788250554425,"version":"build-2803163510"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec id=\"ab-doi240033-4\"><jats:title>Importance<\/jats:title><jats:p>There is a burgeoning interest in therapeutic development for cutaneous neurofibromas (cNFs), a major cause of morbidity in persons with neurofibromatosis type 1 (NF1). To determine meaningful clinical trial outcomes, deeper understanding is needed regarding how cNFs are associated with quality of life (QoL). However, this understanding has been hampered by challenges in recruiting participants with this rare genetic disease.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240033-5\"><jats:title>Objective<\/jats:title><jats:p>To develop a large, crowdsourced validated registry of persons with NF1 and determine the association of specific cNF features with QoL, pain, and itch.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240033-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>From May 2021 to December 2023, a decentralized platform was developed and recruited persons 40 years or older with NF1 and at least 1 cNF from 49 states and 12 countries, who provided clinical survey data, detailed photographs, and genetic sequencing data. Photographs from 583 participants were scored on 12 features of cNFs, including general severity, number, size, facial severity, color, and subtypes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240033-7\"><jats:title>Exposure<\/jats:title><jats:p>cNF features derived from participant-supplied photographs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240033-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Total Skindex scores and subdomain scores (symptoms, emotion, function, pain, and itch).<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240033-9\"><jats:title>Results<\/jats:title><jats:p>Of 583 participants, 384 (65.9%) were female, and the mean (range) age was 51.7 (40.0-83.0) years. Female sex, general severity, number, size, and facial severity of cNFs were negatively associated with QoL, as demonstrated by increased total Skindex scores. QoL had the largest association with the number of cNFs and presence of facial cNFs. Increasing number of cNFs was associated with worse QoL, and even individuals with a low cNF burden (&amp;amp;lt;10 total cNFs) experienced a decrease in QoL.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi240033-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The results of this study suggest that reducing cNF number, particularly on the face, may be associated with improved QoL in individuals with NF1. In addition, early intervention before the development of numerous tumors may lead to the highest benefit in QoL. These data potentially provide insight into which individuals and cNF tumors may benefit most from therapy and highlights the utility of a completely decentralized, photograph-validated and age-controlled study for rare genetic disease. This cohort will allow analysis of disease and tumor heterogeneity after full phenotypic expression is achieved in NF1 and potentially serves as an example in its design for other rare diseases that struggle from poor recruitment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.2912","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:32:48Z","timestamp":1724859168000},"page":"1091","source":"Crossref","is-referenced-by-count":12,"title":["Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1"],"prefix":"10.1001","volume":"160","author":[{"given":"Michelle Jade","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqi","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Vera","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekshika","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandi","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Caroline","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanie","family":"Ramos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G.","family":"Romo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita Y.","family":"Sarin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"doi240033r1","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jid.2022.12.027","article-title":"Cutaneous neurofibroma heterogeneity: factors that influence tumor burden in neurofibromatosis type 1.","volume":"143","author":"Jiang","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi240033r2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"issue":"6","key":"doi240033r3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","article-title":"The Diagnosis and Management of Neurofibromatosis Type 1.","volume":"103","author":"Ly","year":"2019","journal-title":"Med Clin North Am"},{"issue":"16","key":"doi240033r4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136262","article-title":"Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry.","volume":"5","author":"Tabata","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"doi240033r5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2340\/00015555-2241","article-title":"Clinical characteristics of pruritus in neurofibromatosis 1.","volume":"96","author":"Brenaut","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"doi240033r6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12955-017-0607-y","article-title":"Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.","volume":"15","author":"Ferner","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"doi240033r7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-018-0772-z","article-title":"Cutaneous neurofibromas in neurofibromatosis type I: a quantitative natural history study.","volume":"13","author":"Cannon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"doi240033r8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000327379","article-title":"Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients.","volume":"222","author":"Duong","year":"2011","journal-title":"Dermatology"},{"issue":"11","key":"doi240033r9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128881","article-title":"Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.","volume":"5","author":"Chamseddin","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"doi240033r10","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1212\/WNL.0000000000005792","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues.","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"doi240033r11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000517011","article-title":"Mast cells in human cutaneous neurofibromas: density, subtypes, and association with clinical features in neurofibromatosis 1.","volume":"238","author":"Kallionp\u00e4\u00e4","year":"2022","journal-title":"Dermatology"},{"issue":"5","key":"doi240033r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216527","article-title":"The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.","volume":"14","author":"Rice","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"doi240033r13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cge.12551","article-title":"Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life.","volume":"88","author":"Cohen","year":"2015","journal-title":"Clin Genet"},{"issue":"2","key":"doi240033r14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000337548","article-title":"Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image.","volume":"224","author":"Granstr\u00f6m","year":"2012","journal-title":"Dermatology"},{"issue":"7","key":"doi240033r15","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1212\/WNL.0000000000012427","article-title":"Measuring the effect of cutaneous neurofibromas on quality of life in neurofibromatosis type 1.","volume":"97","author":"Maguiness","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"doi240033r16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","article-title":"Clinical research for rare disease: opportunities, challenges, and solutions.","volume":"96","author":"Griggs","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"1","key":"doi240033r17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15386\/cjmed-1015","article-title":"The role of medical registries, potential applications and limitations.","volume":"92","author":"Pop","year":"2019","journal-title":"Med Pharm Rep"},{"issue":"1","key":"doi240033r18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-023-02693-7","article-title":"Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective.","volume":"18","author":"Ghadessi","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"doi240033r19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41746-022-00603-y","article-title":"Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion.","volume":"5","author":"Goodson","year":"2022","journal-title":"NPJ Digit Med"},{"issue":"8","key":"doi240033r20","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/jdv.18140","article-title":"Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.","volume":"36","author":"Fertitta","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi240033r21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic.","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"issue":"2","key":"doi240033r22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life.","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatol Clin"},{"issue":"1","key":"doi240033r23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/imr.12622","article-title":"Mast cell-neural interactions contribute to pain and itch.","volume":"282","author":"Gupta","year":"2018","journal-title":"Immunol Rev"},{"issue":"2","key":"doi240033r24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaad.2014.10.034","article-title":"Pruritus: an underrecognized symptom of small-fiber neuropathies.","volume":"72","author":"Brenaut","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi240033r25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-013-1195-2","article-title":"Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.","volume":"114","author":"Vranceanu","year":"2013","journal-title":"J Neurooncol"},{"key":"doi240033r26","doi-asserted-by":"publisher","first-page":"i141","DOI":"10.1093\/noajnl\/vdaa003","article-title":"Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.","volume":"2","author":"Hamoy-Jimenez","year":"2020","journal-title":"Neurooncol Adv"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2823064\/jamadermatology_lin_2024_oi_240033_1729089077.07448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:07:17Z","timestamp":1729091237000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2823064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.2912","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}